SG Americas Securities LLC Buys 13,328 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

SG Americas Securities LLC grew its position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 38.8% in the fourth quarter, Holdings Channel reports. The fund owned 47,668 shares of the company’s stock after acquiring an additional 13,328 shares during the quarter. SG Americas Securities LLC’s holdings in X4 Pharmaceuticals were worth $40,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. increased its holdings in X4 Pharmaceuticals by 2,547.2% in the 2nd quarter. BlackRock Inc. now owns 9,095,274 shares of the company’s stock worth $17,645,000 after purchasing an additional 8,751,694 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of X4 Pharmaceuticals in the first quarter valued at approximately $3,955,000. Vanguard Group Inc. raised its holdings in X4 Pharmaceuticals by 348.6% in the 3rd quarter. Vanguard Group Inc. now owns 3,208,103 shares of the company’s stock valued at $5,486,000 after buying an additional 2,492,928 shares during the last quarter. State Street Corp boosted its position in X4 Pharmaceuticals by 1,200.8% during the 2nd quarter. State Street Corp now owns 2,219,583 shares of the company’s stock worth $4,306,000 after buying an additional 2,048,950 shares during the period. Finally, Geode Capital Management LLC grew its holdings in X4 Pharmaceuticals by 112.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,350,210 shares of the company’s stock worth $4,559,000 after acquiring an additional 1,241,526 shares during the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

X4 Pharmaceuticals Price Performance

X4 Pharmaceuticals stock opened at $1.26 on Monday. The firm has a market cap of $211.60 million, a P/E ratio of -2.10 and a beta of 0.49. The stock’s 50 day moving average is $1.11 and its 200 day moving average is $0.92. The company has a debt-to-equity ratio of 1.07, a current ratio of 5.34 and a quick ratio of 5.34. X4 Pharmaceuticals, Inc. has a one year low of $0.57 and a one year high of $2.58.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.05. As a group, research analysts expect that X4 Pharmaceuticals, Inc. will post -0.47 EPS for the current year.

Insider Transactions at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 27,721 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at approximately $53,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other X4 Pharmaceuticals news, CEO Paula Ragan sold 49,678 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $0.88, for a total transaction of $43,716.64. Following the transaction, the chief executive officer now owns 765,068 shares in the company, valued at $673,259.84. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Adam S. Mostafa sold 27,721 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $1.01, for a total value of $27,998.21. Following the completion of the sale, the chief financial officer now directly owns 52,500 shares of the company’s stock, valued at $53,025. The disclosure for this sale can be found here. Insiders have sold 185,708 shares of company stock valued at $170,428 in the last 90 days. 1.08% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a research note on Friday, March 22nd.

X4 Pharmaceuticals Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.